About
Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
JNJ
Shares of the drug maker ticked higher by less than 1% premarket after the company reported mixed quarterly financial results. Johnson & Johnson beat profit estimates by 10 cents per share, excluding items. It also missed revenue estimates. Its full-year outlook for earnings was slightly higher than estimates while its revenue forecast was about in line with estimates.
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- J&J trades higher despite Q4 revenue hit by forex, COVID vaccine impact, FY23 outlook above estimates
- Johnson & Johnson Non-GAAP EPS of $2.35 beats by $0.11, revenue of $23.7B misses by $200M
- Johnson & Johnson to report Q4 earnings amid macro concerns
- FDA plans an annual schedule for updated COVID shots
- Morphic says Johnson & Johnson unit ended research collaboration
- AstraZeneca, Biogen, Bristol, and Eli Lilly among companies w/ blockbuster potential drugs
- Catalyst watch: Tesla reverberations, Intel earnings, Rocket Lab launch and Macau stocks on holiday
- Japan to consider downgrading COVID to same level as seasonal flu
- Johnson & Johnson scraps HIV vaccine program after Phase 3 setback
- Johnson & Johnson is scaling back COVID-19 vaccine production – WSJ
- White House COVID coordinator warns winter surges of infections will be new normal
- Medicare to publish drugs targeted for pricing negotiations in September
- Alvotech starts study of biosimilar of J&J's rheumatoid arthritis drug Simponi
- WHO sets Jan. 27 meeting to decide on COVID emergency
- Alvotech, Teva get FDA review for biosimilar to J&J's Stelara
- Fate Therapeutics shares crater ~50% on ending tie-up with Janssen, layoffs
- J&J consumer health spinout Kenvue files for $100M IPO
- J&J, Legend Biotech's Carvykti for multiple myeloma gets review in China
- Align, Invitae among healthcare stocks SA contributors correctly said to avoid in 2022
- Merck is best performing large U.S. pharma of 2022
Earnings History
| Date | EPS / Forecast | Revenue / Forecast | |
|---|---|---|---|
| January 25, 2022 | 2.13 / 2.12 | 24.8B / 25.28B | |
| October 19, 2021 | 2.6 / 2.35 | 23.34B / 23.64B | |
| July 21, 2021 | 2.48 / 2.29 | 23.31B / 22.49B |
Beat! |
| April 20, 2021 | 2.59 / 2.34 | 22.32B / 21.98B |
Beat! |
| January 26, 2021 | 1.86 / 1.82 | 22.48B / 21.66B |
Beat! |
| October 13, 2020 | 2.2 / 1.98 | 21.08B / 20.2B |
Beat! |
| July 16, 2020 | 1.67 / 1.49 | 18.34B / 17.61B |
Beat! |
| April 14, 2020 | 2.3 / 2.02 | 20.69B / 19.73B |
Beat! |
| January 22, 2020 | 1.88 / 1.87 | 20.75B / 20.8B | |
| October 15, 2019 | 2.12 / 2.01 | 20.73B / 20.08B |
Beat! |
| July 16, 2019 | 2.58 / 2.46 | 20.56B / 20.29B |
Beat! |
| April 16, 2019 | 2.1 / 2.04 | 20.02B / 19.61B |
Beat! |
| January 22, 2019 | 1.97 / 1.95 | 20.39B / 20.2B |
Beat! |
| October 16, 2018 | 2.05 / 2.03 | 20.35B / 20.05B |
Beat! |
| July 17, 2018 | 2.1 / 2.07 | 20.83B / 20.42B |
Beat! |
| April 17, 2018 | 2.06 / 2 | 20.01B / 19.49B |
Beat! |
| January 23, 2018 | 1.74 / 1.72 | 20.2B / 20,072M | |
| October 17, 2017 | 1.9 / 1.80 | 19.65B / 19,283M | |
| July 18, 2017 | 1.83 / 1.80 | 18.84B / 18,935M | |
| April 18, 2017 | 1.83 / 1.77 | 17.77B / 18,037M |
| Date | Price | Open | High | Low | Vol | ER | |||
|---|---|---|---|---|---|---|---|---|---|
| Nov 21 | 175.97 | 175.89 |
176.55
|
174.83
|
5.7M | ||||
| Nov 22 | 176.82 | 176.4 |
177.19
|
176.33
|
4.7M | ||||
| Nov 23 | 177.01 | 176.44 |
177.4
|
176.01
|
5.4M | ||||
| Nov 25 | 177.24 | 177.38 |
178.12
|
176.86
|
3.1M | ||||
| Nov 28 | 177.33 | 176.75 |
177.77
|
176.56
|
6.2M | ||||
| Nov 29 | 176.09 | 177.01 |
177.26
|
174.66
|
6.7M | ||||
| Nov 30 | 178 | 176.37 |
178.01
|
174.78
|
13.3M | ||||
| Dec 01 | 178.74 | 179 |
179.96
|
177.77
|
6.3M | ||||
| Dec 02 | 178.88 | 177.5 |
178.96
|
176.96
|
5.8M | ||||